PRME — Prime Medicine, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1894562 ·
Last close
$3.84
Market Cap
$854.20M
52W High
$5.91
52W Low
$2.67
ADV30
5,926,492
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 4,213,000 | — | -39,926,000 | -39,043,000 | 213,855,000 | 54,886,000 | 205,418,000 |
| Jun 2026 | 1,154,000 | — | -43,285,000 | -42,109,000 | 249,040,000 | 47,451,000 | 209,231,000 |
| Mar 2026 | 856,000 | — | -50,654,000 | -49,122,000 | 294,730,000 | 64,106,000 | 218,030,000 |
| Dec 2025 | 838,000 | — | -48,608,000 | -46,079,000 | 342,733,000 | 63,032,000 | 221,865,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-156,051,000
Investing CF
$3,629,000
Financing CF
$146,069,000
CapEx
$-797,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$979,585,000
Inventory
—
Receivables
$120,000
ST Investments
$71,391,000
EBIT TTM
$-196,520,000
Pretax Income TTM
$-187,892,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,061,000
EBITDA
$-175,196,992
Free Cash Flow
$-74,296,624
Enterprise Value
$811,240,640
Total Cash
$61,157,000
Total Debt
$110,421,000
Shares Out
222,448,284
Trailing EPS
$-0.97
Book Value
$0.05
ROE
-207.2%
ROA
-38.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,632,000 | -208,350,000 | -201,142,000 | 342,733,000 | 221,865,000 | 120,868,000 | -162,564,000 |
| Dec 2024 | 2,983,000 | -202,467,000 | -195,882,000 | 297,508,000 | 144,359,000 | 153,149,000 | -122,865,000 |
| Dec 2023 | 0 | -191,292,000 | -198,133,000 | 193,851,000 | 60,780,000 | 133,071,000 | -165,412,000 |
| Dec 2022 | 0 | -116,544,000 | -121,821,000 | 360,314,000 | 44,044,000 | 316,270,000 | -131,827,000 |
TTM Snapshot
Revenues TTM
$3,872,000
NetIncome TTM
$-187,892,000
OpCashFlow TTM
—
Assets (Latest)
$249,040,000
Forward EPS
$-0.83
Max Pain — expiry 2027-01-15
max pain strike: $4.00 · spot: $3.82 · call oi: 9,605 · put oi: 3,222
Expected Move to 2027-01-15:
±$1.25
(32.72%) —
implied range
$2.57 –
$5.07
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BBTX | Bambusa Therapeutics, Inc. | $832.91M | $16.35 | — |
| MGTX | MeiraGTx Holdings plc | $826.80M | $8.46 | — |
| ODTX | Odyssey Therapeutics, Inc. | $931.07M | $19.37 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $775.03M | $9.07 | — |
| IMTX | Immatics N.V. | $957.50M | $6.29 | — |
News headlines (Yahoo Finance, 1h cache)
Prime Medicine's Financing Removes Major Overhang With Major Upside Opportunities in 2027, Oppenheimer Says
2026-11-13 17:05 · Yahoo
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 21:25 · Yahoo
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2026-11-12 21:15 · Yahoo
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-12 21:01 · Yahoo
Prime Medicine Announces Pricing of Public Offering of Common Stock
2026-11-11 02:40 · Yahoo
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
2026-11-10 21:05 · Yahoo
Prime Medicine to Present at Jefferies Global Healthcare Conference
2026-11-09 13:00 · Yahoo
Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
2026-10-29 06:41 · Yahoo
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
2026-10-28 19:34 · Yahoo
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
2026-10-12 15:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.